860032-33-3

Upstream product

• 530084-80-1 8-benzyloxy-5-[(R)-2-[2-(4-bromo-phenyl)-ethylamino]-1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-1H-quinolin-2-one hydrochloride 
• 900523-76-4 4-(2-amino-2-methyl-propoxy)-phenylamine hydrochloride 
• 63335-17-1 2-methyl-1-(4-nitrophenoxy)propan-2-amine 
• 350-46-9 4-Fluoronitrobenzene 
• 743461-36-1 8-benzyloxy-5-[(R)-2-[2-(4-bromophenyl)ethylamino]-1-(tert-butyldimethylsilanyloxy)ethyl]-1H-quinolin-2-one 
• 860032-57-1 4-(2-amino-2-methyl-propoxy)-phenylamine 
• 73918-56-6 4-Bromophenethylamine 
• 530084-74-3 (R)-8-(benzyloxy)-5-(2-bromo-1-((tert-butyldimethylsilyl)oxy)ethyl)quinolin-2(1H)-one 

Downstream Products

• 860032-25-3 TD-4306 
• 860032-34-4 5-[(R)-2-(2-{4-[4-(2-amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-1-hydroxy-ethyl]-8-benzyloxy-1H-quinolin-2-one 

Relevant academic research and scientific papers

Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD

A multivalent approach focused on amine-based secondary binding groups was applied to the discovery of long-acting inhaled β2-agonists. Addition of amine moieties to the neutral secondary binding group of an existing β2-agonist serie

CINNAMATE SALTS OF A BETA-2 ADRENERGIC AGONIST

This invention relates to cinnamate salts of 5- [ (R) -2- (2-andlcub ; 4- [4- (2-amino-2-methyl-propoxy) -phenyl amino] -phenyl andrcub ; -ethylamino) -1 -hydroxy- ethyl] -8-hydroxy-lH-quinolin-2-one ,which may be depicted by the structural Formula (I).

Aryl aniline derivatives as beta2 adrenergic receptor agonists

The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic